48 results about "Cancer research" patented technology

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various genetic markers associated with an increased risk of having or developing aggressive prostate cancer.

The invention relates to a reagent kit for detecting clear renal cell carcinoma. The clear renal cell carcinoma is carcinoma being high in proportion of carcinoma of the kidney, but a detection method has a certain limitation and is not suitable for inexpensive and massive popularization. According to the reagent kit provided by the invention, the content of DUSP-9 protein in samples can be idiosyncratically detected, so that the clear renal cell carcinoma can be rapidly and efficiently detected. The reagent kit is simple to prepare, low in cost, and suitable for large-area popularization and application.

The invention relates to application of a Sultan-cyclohexanone spiro derivative 1-3-51 in preparation of a medicine for treating gastric cancer, the medicine remarkably inhibits expression of FOXM1 and proliferation, invasion and migration of gastric cancer cells, and after interfering with FOXM1, the capacity of inhibiting proliferation, invasion and migration of gastric cancer cells is reduced.

An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.

The invention concerns antibodies which is specific for SM5-1 antigen expressed in melanoma, breast cancer and hepatocellular carcinoma, and polynucleotides encoding the antibodies. The invention further concerns use of such antibodies and / or polynucleotides in diagnosing and treating malignancies.

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.

The invention belongs to the field of biological medicine, and relates to application of TROAP in preparation of renal cell carcinoma prognosis products and therapeutic drugs. Experiments find and prove that the TROAP gene can promote proliferation, migration and invasion of renal carcinoma cells and inhibit apoptosis at the same time, and is a very important marker for renal carcinoma progression. On the basis, the TROAP gene is used as a screened molecular marker, the prognosis condition of a renal cell carcinoma patient is judged by detecting the expression level of the TROAP, clinical treatment is guided through a prognosis model, and the application has important practical application value for evaluating the prognosis of the patient and guiding the individualized treatment of the patient. Meanwhile, the ROAP gene serves as a targeted drug development action target, a new inhibitor and a new drug development target are provided for the renal clear cell carcinoma, especially metastatic clear cell carcinoma, and the early warning capacity and the subsequent treatment effect on the patients of the type are improved.

The invention belongs to the technical field of biology, and relates to application of a reagent for detecting TRIM45 expression level in preparation of a hepatocellular carcinoma diagnosis and treatment preparation. The invention finds that TRIM45 is related to occurrence and development of hepatocellular carcinoma for the first time. Through bioinformatics analysis, it is found that TRIM45 has a high AUC value in hepatocellular carcinoma patients, and it is prompted that TRIM45 serving as the diagnosis marker of hepatocellular carcinoma has high accuracy and specificity. According to mRNA-seq data and clinical data from a cancer genome map database, it is verified that the expression level of TRIM45 can affect survival of hepatocellular carcinoma patients, it is prompted that TRIM45 has correlation with hepatocellular carcinoma, research on pathogenesis of hepatocellular carcinoma will be further enriched, and the application of the TRIM45 to the hepatocellular carcinoma is promoted. And a novel tumor marker and a novel therapeutic target are provided for diagnosis and prognosis monitoring of hepatocellular carcinoma.